• Achilles tendon injury
• Fibrosis
• Gastrocnemius muscle
• Inflammation
• PRP
• Remodeling
• Therapeutic

• Animals
• Achilles Tendon/metabolism
• Achilles Tendon/injuries
• Achilles Tendon/pathology
• Platelet-Rich Plasma/metabolism
• Muscle, Skeletal/metabolism
• Muscle, Skeletal/pathology
• Muscle, Skeletal/injuries
• Matrix Metalloproteinase 9/metabolism
• bcl-2-Associated X Protein/metabolism
• Rats
• Male
• Fibrosis
• HMGB1 Protein/metabolism
• HMGB1 Protein/genetics
• Disease Models, Animal
• Insulin-Like Growth Factor I/metabolism
• Insulin-Like Growth Factor I/genetics
• Tendon Injuries/therapy
• Tendon Injuries/pathology
• Tendon Injuries/metabolism
• Gene Expression Regulation
• Wound Healing
• Rats, Sprague-Dawley
• Rats, Wistar

• Mesenchymal stem cell
• Meta-analysis
• Retinitis pigmentosa
• Stem cell therapies
• Systematic review

• Humans
• Retinitis Pigmentosa/therapy
• Mesenchymal Stem Cell Transplantation/methods
• Visual Acuity
• Treatment Outcome
• Quality of Life
• Mesenchymal Stem Cells

• Autologous platelet-rich plasma
• Autologous serum
• Cornea
• Dry eye disease
• Epitheliotrophic factors

• 64004 Faculty of Medicine Ramathibodi Hospital, Mahidol University
• Faculty of Medicine Ramathibodi Hospital, Mahidol University

• Autologous blood
• Cytokines
• Dry eye
• Ocular surface disorder
• Tear film

• blood component therapy
• dry eye disease
• network meta-analysis
• randomized controlled trial
• systematic review

• Age-related macular degeneration
• Cord blood platelet- rich plasma
• Macular degeneration
• Macular surgery
• Vitreoretinal surgery

• Alkali burn injury
• Anterior segment optical coherence tomography
• Citrate
• Corneal wound healing
• Hydrogel
• Platelet-rich plasma

• Animals
• Tomography, Optical Coherence
• Burns, Chemical/drug therapy
• Eye Burns/chemically induced
• Rats
• Wound Healing/drug effects
• Wound Healing/physiology
• Disease Models, Animal
• Alginates
• Male
• Platelet-Rich Plasma
• Hydrogels
• Matrix Metalloproteinase 9/metabolism
• Rats, Sprague-Dawley
• Enzyme-Linked Immunosorbent Assay
• Interleukin-1beta/metabolism
• Corneal Injuries/chemically induced
• Anterior Eye Segment/diagnostic imaging

• Autologous PRP
• Autologous serum
• Dry eye
• Persistent epithelial defect

• Autologous conditioned plasma
• Cytotoxic cells
• Epithelization
• Histocompatibility
• Transplantation

• Rabbits
• Animals
• Keratoplasty, Penetrating/methods
• Serum
• Cornea
• Corneal Opacity
• Corneal Neovascularization
• Platelet-Rich Plasma
• Umbilical Cord

• Dry eye disease
• Platelet-rich plasma
• Symptoms
• Tear quality
• Tear quantity

• Humans
• Prospective Studies
• Quality of Life
• Systematic Reviews as Topic
• Meta-Analysis as Topic
• Dry Eye Syndromes/therapy
• Dry Eye Syndromes/metabolism
• Platelet-Rich Plasma/metabolism

• In vitro fertilisation
• platelet-rich plasma
• recurrent implantation failure

• cell growth
• cell proliferation
• ciliogenesis
• differentiation
• regeneration

• Animals
• Corneal Ulcer/veterinary
• Equidae
• Platelet-Rich Fibrin
• Wound Healing

• Assiut University

• Bioadhesive hydrogel
• Biomaterial
• Corneal regeneration
• Limbal stem cell deficiency
• Ocular surface chemical injury
• Platelet-rich plasma (PRP)

• Hydrogels/chemistry
• Cornea
• Intercellular Signaling Peptides and Proteins
• Platelet-Rich Plasma/chemistry
• Platelet-Rich Plasma/metabolism
• Contact Lenses

• 220S674 Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (TÜBİTAK)
• TOA-2022-2458 Eskisehir Osmangazi University Scientific Research Projects

• Sjogren’s syndrome
• allogeneic platelet rich plasma
• autoimmune ocular surface disorders
• dry eye disease (DED)
• growth factors

• Corneal ulcers
• Growth factors
• Keratoconjunctivitis sicca
• Platelet-rich plasma
• Regenerative medicine

• Animals
• Ophthalmology
• Wound Healing/physiology
• Eye Diseases/veterinary
• Platelet-Rich Plasma/physiology

• extracellular vesicles
• inflammation
• platelet derivatives
• platelets

• Humans
• Blood Platelets/physiology
• Hemostasis/physiology
• Thrombosis
• Blood Coagulation
• Adaptive Immunity

• AMG
• PRP
• Perforated corneal ulcer
• Stromal lenticule obtained from small-incision lenticule extraction (SMILE) surgery

• dogs
• homologous platelet-rich plasma
• keratoconjunctivitis sicca
• tacrolimus 0.03%

This article discusses common ocular manifestations of cystic fibrosis (CF) and cystic fibrosis transmembrane conductance regulator-related disorders (CFTR-RD). A structured approach for assessing and treating patients with CF/CFTR-RD seeking corneal refractive surgery is proposed, as well as a novel surgical risk scoring system. We also report two patients with various manifestations of CFTR dysfunction who presented for refractive surgery and the outcomes of the procedures. Surgeons seeking to perform refractive surgery on patients with CF/CFTR-RD should be aware of mild to severe clinical manifestations of CFTR dysfunction. Specific systemic and ocular manifestations of CF include chronic obstructive pulmonary disease (COPD), bronchiectasis, recurrent pulmonary infections, CF-related diabetes and liver disease, pancreatic insufficiency, conjunctival xerosis, night blindness, meibomian gland dysfunction (MGD), and blepharitis. Corneal manifestations include dry eye disease (DED), punctate keratitis (PK), filamentary keratitis (FK), xerophthalmia, and decreased endothelial cell density and central corneal thickness. Utilization of the appropriate review of systems (ROS) and screening tests will assist in determining if the patient is a suitable candidate for refractive surgery, as CF/CFTR-RD can impact the health of the cornea. Collaboration with other medical professionals who care for these patients is encouraged to ensure that their CF/CFTR-RD symptoms are best controlled via systemic and other treatment options. This will assist in reducing the severity of their ocular manifestations before and after surgery.

• Humans
• NF-kappa B/metabolism
• Synovial Fluid/metabolism
• Apoptosis
• Fibroblasts/metabolism
• Platelet-Rich Plasma/metabolism
• Osteoarthritis/therapy
• Osteoarthritis/metabolism
• Inflammation/metabolism
• Cells, Cultured

Methods of sclerotomy closure following a vitrectomy, including the use of sutures, have been associated with complications such as inflammation, foreign body sensation, and infection. Here, we test an innovative approach to scleral wound closure following pars plana vitrectomy that involves plugging the wound. We investigated several materials with the intent of using products that were either already approved by the FDA for other types of procedures or were biocompatible patient-derived materials.

We examined whether scleral wounds could be sealed by a clot or internal “plug” rather than a suture or an external adhesive. We tested patient-derived materials (platelet-rich plasma (PRP) and whole blood) as well as polyethylene glycol (PEG) sealant. Whole blood and PRP were prevented from clotting prematurely using sodium citrate, and were clotted for the study with thrombin. Polyethylene glycol (PEG) sealant was prepared according to manufacturer’s recommendations. We used fresh-frozen cadaveric porcine eyes. We tested several methods to form plugs using the above materials, as well as various methods to deliver the plugs into the sclerotomy incisions. We used a novel technique of manual vitrectomy. Successfully generated and implanted clots were tested for efficacy with the Seidel test.

Polyethylene glycol (PEG) sealant fractured during our attempts at molding and inserting the plug. In contrast, both whole blood and PRP yielded successful plugs for insertion. We molded a whole blood clot plug by allowing it to clot inside a 20-gauge angiocath catheter and we successfully delivered it through a 23G trocar. At baseline, no wound leakage was apparent. However, the whole blood clot dislodged during the Seidel test. We successfully molded and delivered a PRP clot plug using a tapered 2-20 μl pipette tip, using MAXGrip Forceps to push it through into the wound. No scleral wound leakage was noted at our baseline physiologic infusion pressure. Furthermore, the PRP clot plug prevented scleral wound leakage up to a pressure of 60 mmHg and was confirmed with the Seidel test.

Our findings suggest that insertion of a clot plug made from either whole blood or PRP may be an effective strategy for scleral wound closure following pars plana vitrectomy. Further testing in preclinical models is warranted to further refine the materials and methods, since this appears to have the potential to improve the closure of the scleral wounds after pars plana vitrectomy.

Platelet concentrates (PCs), including platelet-rich plasma (PRP) gel and platelet-rich fibrin (PRF), are autologous blood-derived biomaterials containing numerous growth factors. This study aimed to evaluate the initial healing effects of PRP gel and PRF on deep corneal wounds. Thirty-three eyes from New Zealand white rabbits were divided into four groups: group 1, lamellar keratectomy (LK); group 2, LK + commercial porcine small intestinal submucosal membrane (SIS); group 3, LK + SIS + PRP gel; and group 4, LK + SIS + PRF. Postoperative clinical and histological findings were observed for eight weeks. Group 1 showed no neovascularization during the observation period, and incompletely recovered with a thin cornea. Group 2 showed active healing through neovascularization, and a thick cornea was regenerated through the sufficient generation of myofibroblasts. Although group 3 showed a healing effect similar to that of group 2, angiogenesis and subsequent vessel regression were promoted, and corneal opacity improved more rapidly. In group 4, angiogenesis was promoted during initial healing; however, the incidence of complications, such as inflammation, was high, and myofibroblasts were hardly generated in the corneal stroma, which adversely affected remodeling. In conclusion, while PRP gel is a safe surgical material for promoting remodeling through vascular healing and myofibroblast production in deep corneal wounds, the use of PRF is not recommended.

Corneal disease is one of the most significant causes of blindness around the world. Presently, corneal transplantation is the only way to treat cornea blindness. It should be noted that the amount of cornea that people donate is so much less than that required (1:70). Therefore, scientists have tried to resolve this problem with tissue engineering and regenerative medicine. Fabricating cornea with traditional methods is difficult due to their unique properties, such as transparency and geometry. Bioprinting is a technology based on additive manufacturing that can use different biomaterials as bioink for tissue engineering, and the emergence of 3D bioprinting presents a clear possibility to overcome this problem. This new technology requires special materials for printing scaffolds with acceptable biocompatibility. Hydrogels have received significant attention in the past 50 years, and they have been distinguished from other materials because of their unique and outstanding properties. Therefore, hydrogels could be a good bioink for the bioprinting of different scaffolds for corneal tissue engineering. In this review, we discuss the use of different types of hydrogel for bioink for corneal tissue engineering and various methods that have been used for bioprinting. Furthermore, the properties of hydrogels and different types of hydrogels are described.

• Artificial tear
• OSDI
• autologous platelet-rich plasma
• dry eye disease

• Adult
• Aged
• Dry Eye Syndromes/diagnosis
• Dry Eye Syndromes/therapy
• Humans
• Lubricant Eye Drops
• Middle Aged
• Platelet-Rich Plasma
• Prospective Studies

• hy-tissue PRP
• autologous platelet-rich plasma (PRP)
• complete limbal stem cell deficiency
• firework-related injuries
• ocular burn
• very pure PRP

• IGF-1
• PDGF
• Platelet growth factors
• Platelet-rich plasma
• Regenerative potential
• TGF
• VEGF

• Corneal ulceration
• interleukin-6
• platelet-rich plasma

• Corneal perforation
• amniotic membrane
• platelet-rich plasma (PRP).

• Blood Coagulation
• Blood Platelets
• Fibrin
• Humans
• Thrombosis
• Wound Healing

• R01 HL155330 NHLBI NIH HHS
• R21 EB026591 NIBIB NIH HHS
• R35 HL145000 NHLBI NIH HHS

• adverse events
• corneal and external diseases
• statistics & research methods

• Dry Eye Syndromes/drug therapy
• Humans
• Lubricant Eye Drops
• Platelet-Rich Plasma
• Quality of Life
• Randomized Controlled Trials as Topic
• Tears
• Thailand
• Treatment Outcome

• Faculty of Medicine, Ramathibodi Hospital, Mahidol University

• cornea
• fibrosis
• microRNAs
• protein therapy
• wound healing

• Cornea
• Corneal epithelial defect
• Corneal injury
• Exposure keratopathy
• Ocular wound chamber
• Platelet lysate

• Animals
• Blood Platelets/metabolism
• Corneal Injuries/pathology
• Corneal Injuries/therapy
• Epithelium, Corneal/injuries
• Epithelium, Corneal/pathology
• Humans
• Re-Epithelialization/physiology
• Tomography, Optical Coherence
• Wound Healing

Human platelet products have emerged as an alternative treatment for a range of ocular surface diseases such as dry eye and corneal ulceration. With significant therapeutic potential and increasing popularity, this study aimed to conduct a systematic review to detail the various production methods involved in generating platelet-derived products, compare and analyze clinical findings across available studies, and disseminate the relative advantages, limitations, and challenges of using platelet products to treat ocular surface disease. Thirty-eight clinical studies were identified, excluding studies conducted in animals and non-English language. Studies reported clinical outcomes, which included ocular surface disease index, best-corrected visual acuity, and corneal fluorescein staining. Most clinical studies reported improved patient signs and symptoms with an increasing variety of human platelet products including platelet rich plasma eye drops, human platelet lysate and platelet gels. However, due to variations in production methods, and study designs as well as confusing terminology, it was suggested that characterization of platelet products is needed for proper evaluation across studies.

• dry eye syndrome
• human platelet lysate
• platelet rich plasma

• platelet extract
• regenerative medicine
• tissue engineering

Ocular chemical burns are absolute ophthalmic emergencies and require immediate management to minimize devastating sequelae. Management of alkali and acid burns is started at the scene of the accident by copious irrigation. Treatment is directed at improving epithelial integrity and stromal stability, reduction of undue inflammation, and prevention or timely management of complications. To ascertain the best possible outcome, numerous biological medications and surgical interventions have been merged into conventional therapeutic regimens. These include autologous and umbilical cord serum preparations, platelet-rich plasma, amniotic membrane transplantation, limbal stem-cell transplantation, and anti-angiogenic agents.

• amniotic membrane transplantation
• autologous serum
• limbal stem cell transplantation
• ocular chemical burn

Manufacturing of mesenchymal stromal cell (MSC)-based therapies for regenerative medicine requires the use of suitable supply of growth factors that enhance proliferation, cell stability and potency during cell expansion. Human blood derivatives such as human platelet lysate (hPL) have emerged as a feasible alternative for cell growth supplement. Nevertheless, composition and functional characterization of hPL in the context of cell manufacturing is still under investigation, particularly regarding the content and function of pro-survival and pro-regenerative factors. We performed comparative analyses of hPL, human serum (hS) and fetal bovine serum (FBS) stability and potency to support Wharton’s jelly (WJ) MSC production. We demonstrated that hPL displayed low inter-batch variation and unique secretome profile that was not present in hS and FBS. Importantly, hPL-derived factors including PDGF family, EGF, TGF-alpha, angiogenin and RANTES were actively taken up by WJ-MSC to support efficient expansion. Moreover, hPL but not hS or FBS induced secretion of osteoprotegerin, HGF, IL-6 and GRO-alpha by WJ-MSC during the expansion phase. Thus, hPL is a suitable source of factors supporting viability, stability and potency of WJ-MSC and therefore constitutes an essential raw material that in combination with WJ-MSC introduces a great opportunity for the generation of potent regenerative medicine products.

• Wharton’s Jelly Mesenchymal Stromal Cells
• cytokines
• human growth factors
• human platelet lysate

The purpose of this study was to quantify the presence of growth factors (GFs) and fibronectin in autologous platelet-rich plasma for topical ocular use (E-PRP) comparing their concentration when different preparation and preservation procedures were applied.

E-PRP was prepared with blood from healthy volunteers. The count of platelets, leukocytes, and red blood cells in the whole blood and E-PRP were performed. The concentration of the GFs platelet-derived growth factor BB (PDGF-BB), transforming growth factor β1 (TGF-β1), epidermal growth factor (EGF), vascular endothelial growth factor A (VEGF-A), and fibronectin was determined in each of the four procedures applied including fresh, frozen at −20°C for 3 months, fresh-spin, and frozen-spin at −20°C E-PRP samples. Posterior statistical analysis was performed to establish significant differences between groups and between GFs in relation to the amounts of platelets.

Platelets in the E-PRP doubled in the number of basal values of whole blood (P ≤ 0.01). The blood cells in the E-PRP decreased drastically in red cells (99%) and also in leukocytes (82%). The concentration of PDGF-BB and EGF was significantly higher (P < 0.01) when the E-PRP samples were frozen at −20°C. However, no significant differences were observed for TGF-β1, VEGF-A, and fibronectin (P > 0.05). The concentration of GFs in the E-PRP did not necessarily correlate with the number of platelets.

Freezing the E-PRP for 3 months at −20°C increased the concentration of important proteins, such as PDGF-BB and EGF, and maintained the levels of others. These findings are essential because treatments, such as E-PRP, used by patients with ocular surface dysfunctions tend to prolong it in time. In addition, subsequent centrifugation of the E-PRP decreased the values of TFG-β1, but not the other GFs, which would allow adjusting the concentration of TFG-β1, as necessary. This procedure guarantees their correct conservation and viability.

This work demonstrates how clinical application can be improved by starting from basic research. The quantification of GFs and fibronectin in platelet-rich plasma (PRP) helps to clarify which is the best mode of preparation and preservation of PRP for clinical applications. This allows to optimize the product that is delivered to the patients as a treatment for the dysfunctions of the ocular surface, guaranteeing that the conservation does not affect at all the quality of the PRP that it is going to be used.

• E-PRP
• PRP
• autologous
• cornea
• eye drops
• growth factors
• plasma
• platelet rich plasma

To evaluate the efficacy of a low-cost preparation of platelet-rich plasma (PRP) eye drops in the treatment of persistent non-infectious corneal ulcer.

A 67-year-old female presented to our clinic with a wide corneal ulcer and severe paracentral corneal thinning refractory to medical therapy with antibiotics, lubricant and contact lens bandage. The patient received a novel preparation of PRP solution. After 15 days of therapy, we observed complete resolution of the corneal ulcer with regrowth of the epithelium and a reduction in corneal opacity.

Although the low-cost PRP preparation gives a lower platelet concentration than standard procedures, our work shows this preparation to be effective in the treatment of refractory non-infectious corneal ulcer.

• Corneal ulcer
• Platelet-rich plasma
• Refractory ulcer

Intraovarian platelet-rich plasma (PRP) infusion was recently introduced in the context of addressing ovarian insufficiency. Reporting on its effectiveness prior to adopting in clinical routine practice is imperative. This study aims to provide pilot data regarding PRP application for ovarian rejuvenation. Four pilot studies were conducted on poor ovarian response (POR), premature ovarian insufficiency (POI), perimenopause, and menopause, respectively. Each pilot study reports on thirty patients, 120 participants were recruited in total. All participants provided written informed consent prior to treatment. Primary outcome measures for the POR pilot study were levels of anti-müllerian hormone (AMH), antral follicle count (AFC) and oocyte yield. For the POI, perimenopausal and menopausal pilot studies primary outcome measures were restoration of menstrual cycle, and Follicle Stimulating Hormone (FSH) levels. A significant improvement on the hormonal profile and the ovarian reserve status was noted, along with improved intracytoplasmic sperm injection (ICSI) cycle performance concerning POR participants. Menstruation recovery was observed in 18 out of 30 POI patients, along with a statistically significant improvement on levels of AMH, FSH, and AFC. Similarly, 13 out of 30 menopausal women positively responded to PRP treatment. Finally, menstruation regularity, improved hormonal levels and AFC were reported for 24 out of 30 perimenopausal women. To conclude, PRP infusion appears to convey promising results in addressing ovarian insufficiency.

• Platelet-rich plasma
• intraovarian infusion
• menopause
• ovarian rejuvenation
• ovarian reserve
• perimenopause
• poor responders
• premature ovarian insufficiency

Platelet lysate produced from platelet apheresis components has been proposed as an alternative to serum eye drops in the treatment of ocular surface disease. This study compared the effects of platelet lysate and serum on growth factor, cytokine and nanoparticle concentrations, and corneal epithelial cell proliferation.

The concentration of growth factors, cytokines, and nanoparticles in platelet lysates manufactured from either fresh or expired platelet apheresis concentrations collected with Trima or Haemonetics technology was characterized and compared with those of allogeneic, autologous, and fetal calf serum. The ability to promote corneal epithelial cell proliferation and wound healing was tested in vitro.

Platelet lysate enriched the amount of transforming growth factor β1, platelet-derived growth factor –AB and –BB, fibroblast growth factor, and epidermal growth factor compared with the two sera groups. The concentrations of insulin-like growth factor 1, hepatocyte growth factor, and fibronectin were significantly lower than in sera. There were no differences in nanoparticle concentrations. There was no significant difference in corneal epithelial cell proliferation. Platelet lysates were comparable to fetal calf serum in accelerating corneal epithelial wound healing in vitro.

Fresh and expired platelet lysates from the Trima and Haemonetics systems had higher growth factor concentrations than sera. The ability of platelet lysates to promote corneal epithelial cell proliferation and wound healing was equivalent to sera.

Platelet lysates may serve as an efficient and reliable source of human growth factors for the treatment of ocular surface diseases.

• cornea
• epithelium
• growth factors
• platelet lysate
• serum